Volunteer for NIAID-funded clinical studies related to immune tolerance on ClinicalTrials.gov.
As the leading NIH Institute for research in immunology, the NIAID is in a unique position to capitalize on advances in basic, pre-clinical and clinical research focused on achieving immune tolerance for immune-mediated diseases, including autoimmune and allergic diseases as well as transplant rejection. This research plan provides a broad-based set of strategies and initiatives to further our understanding of immune tolerance and to accelerate the clinical evaluation of tolerogenic approaches to treat and prevent immune system diseases.
The plan provides an effective model for translational research and for ensuring that key studies are performed in a coordinated and efficient manner. The plan is designed around a mechanism-based (as opposed to a disease-oriented) approach, focusing on immune tolerance as the overall scientific framework and clinical objective. The goal is to begin a more collaborative and coordinated research effort-one involving basic immunologists, relevant clinical specialties, other NIH Institutes and the pharmaceutical and biotechnology industry. Major features of the plan are outlined below.
Establish new, and use existing, clinical research infrastructures to accelerate multi-center studies, including cooperative clinical trial groups in kidney transplantation, islet transplantation, autoimmune and allergic diseases.
Incorporate studies of underlying mechanisms in non-human primate and clinical research.
Incorporate developmental work to identify and validate surrogate markers of immune tolerance as well as disease stage, activity and therapeutic response.
Engage the participation of the pharmaceutical and biotechnology industry by creating an infrastructure that will accelerate quality pre-clinical and clinical research.
Support basic research to expand knowledge of the molecular basis for tolerance induction and maintenance and innovative research to expand the universe of tolerogenic approaches.
Ensure the availability of critical research resources, including research training programs for physicians and Ph.D.s.
Co-stimulatory blockade (e.g., anti-CD40 ligand, anti-B7, CTLA4-Ig)
Cytokine modulation (e.g., IL-4, IL-12, TNF, TGFß
Deletion of responding lymphocytes (e.g., Fas-ligand)
Other approaches, such as leukocyte migration blockade, peptide-based therapies targeted at specific antigens, and the use of molecularly engineered cells and tissues for deletion or inactivation of pathogenic lymphocytes.
Type 1 Diabetes Mellitus
Systemic Lupus Erythematosus
Asthma and Allergic Diseases
Human Immunology Cooperative Study Groups
Basic Studies for Future Discovery
back to top
Last Updated September 28, 2010
Last Reviewed September 16, 2010